Genmab describes Darzalex-fueled pipeline

Genmab A/S (CSE:GEN; OTCBB:GMXAY) hopes to put at least four new candidates into the clinic over the next four years using revenue from newly approved multiple myeloma (MM) drug Darzalex daratumumab. The company also presented data from a Phase I/II study of Darzalex plus Revlimid lenalidomide and dexamethasone showing improved response and survival rates over the other two drugs alone.

During an R&D presentation on Tuesday, President and CEO Jan van de Winkel said Genmab hopes Darzalex will become a "transformational molecule" for Genmab, though he noted that if sales are slower than expected, Genmab can still pursue its pipeline programs with existing cash. CFO David Eatwell said Genmab has nearly $500 million in cash on hand. ...